Treatments for TD: limited evidence, high cost

Treatments for TD: limited evidence, high cost PharmacoEconomics & Outcomes News 792, p4 - 2 Dec 2017 Treatments for TD: limited evidence, high cost The evidence of the clinical benefit and long-term safety of valbenazine and deutetrabenazine for the treatment of tardive dyskinesia (TD) is uncertain, and these agents are not cost effective at current wholesale acquisition cost (WAC). These are the main findings of an evidence report, released by the Institute for Clinical and Economic Review (ICER), which assessed the comparative clinical effectiveness and value of valbenazine [Ingrezza], deutetrabenazine [Austedo] and tetrabenazine [Xenazine] for management of TD. For valbenazine and deutetrabenazine, the report found inconclusive evidence for the treatment of TD, mainly due to uncertainty surrounding key outcome measures studied in clinical trials, as well as a lack of long-term safety data. For tetrabenazine, the evidence was insufficient to assess its net health benefit. Economic analyses showed that both valbenazine and deutetrabenazine were not cost effective at $US752 000 and $1.1 million per QALY, respectively. The analyses also showed that the annual WAC of valbenazine (currently $76 000) would need to fall to $7600–$11 260, a discount of 85%–90%, to align the cost with the benefit provided to patients. Similarly, the annual WAC of deutetrabenazine (currently $90 000) would need to fall to $6200–$9200, a discount of 90%–93%. Tetrabenazine was not included in these economic analyses due to data limitations. ICER. Institute for Clinical and Economic Review report finds evidence limited on treatments for tardive dyskinesia; discounts of up to 90% needed to align cost of drugs with benefit to patients. Internet Document : 21 Nov 2017. Available from: URL: https://icer-review.org/announcements/tardive-dyskinesia-evidence-report/ 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Treatments for TD: limited evidence, high cost

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/treatments-for-td-limited-evidence-high-cost-98xzizXVoU
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4527-1
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p4 - 2 Dec 2017 Treatments for TD: limited evidence, high cost The evidence of the clinical benefit and long-term safety of valbenazine and deutetrabenazine for the treatment of tardive dyskinesia (TD) is uncertain, and these agents are not cost effective at current wholesale acquisition cost (WAC). These are the main findings of an evidence report, released by the Institute for Clinical and Economic Review (ICER), which assessed the comparative clinical effectiveness and value of valbenazine [Ingrezza], deutetrabenazine [Austedo] and tetrabenazine [Xenazine] for management of TD. For valbenazine and deutetrabenazine, the report found inconclusive evidence for the treatment of TD, mainly due to uncertainty surrounding key outcome measures studied in clinical trials, as well as a lack of long-term safety data. For tetrabenazine, the evidence was insufficient to assess its net health benefit. Economic analyses showed that both valbenazine and deutetrabenazine were not cost effective at $US752 000 and $1.1 million per QALY, respectively. The analyses also showed that the annual WAC of valbenazine (currently $76 000) would need to fall to $7600–$11 260, a discount of 85%–90%, to align the cost with the benefit provided to patients. Similarly, the annual WAC of deutetrabenazine (currently $90 000) would need to fall to $6200–$9200, a discount of 90%–93%. Tetrabenazine was not included in these economic analyses due to data limitations. ICER. Institute for Clinical and Economic Review report finds evidence limited on treatments for tardive dyskinesia; discounts of up to 90% needed to align cost of drugs with benefit to patients. Internet Document : 21 Nov 2017. Available from: URL: https://icer-review.org/announcements/tardive-dyskinesia-evidence-report/ 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off